Entering text into the input field will update the search result below

CorMedix's (CRMD) CEO Khoso Baluch on Q3 2018 Results - Earnings Call Transcript

Nov. 14, 2018 9:11 PM ETCorMedix Inc. (CRMD)2 Comments
SA Transcripts profile picture
SA Transcripts

CorMedix Inc. (NASDAQ:CRMD) Q2 2018 Earnings Conference Call August 14, 2018 4:30 PM ET


Dan Ferry – Investor Relations-LifeSci Advisors

Khoso Baluch – Chief Executive Officer

Liz Masson – Executive Vice President and Head-Clinical Operations

Paul Chew – Chief Medical Officer

Bob Cook – Chief Financial Officer


Julian Harrison – H. C. Wainwright


Greetings, and welcome to CorMedix Third Quarter 2018 Investor Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded.

It is now pleasure to introduce your host Dan Ferry, LifeSci Advisors. Please go ahead.

Dan Ferry

Thank you. Good afternoon. And welcome to the CorMedix third quarter 2018 investor conference call.

Leading the call today is, Khoso Baluch, Chief Executive Officer of CorMedix. He is joined by Bob Cook, Chief Financial Officer; Liz Masson, Executive Vice President and Head of Clinical Operations; and Paul Chew, Chief Medical Officer.

After the prepared remarks, we will open up the call for Q&A.

Before we begin, I would like to remind everyone that during the call management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include, but are not limited to, any of the following.

Any statements other than statements of historical fact regarding management’s expectations, beliefs, goals, and plans about the Company’s prospects, including its clinical development program for Neutrolin in the U.S. and other product candidates, future financial position, future revenues and projected costs, and potential market acceptance of Neutrolin and other product candidates.

More specifically, forward-looking statements include any statements about our clinical development plans and the timing, costs, results, and interpretations thereof, projections

Recommended For You

Comments (2)

Why is dropping today ?
crmd is the best
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.